UPADACITINIB
upadacitinib 15 mg modified release tablet, 28
UPADACITINIB (12835M)
12835M
Manner of administration:Oral
Restriction
Indication: Chronic severe atopic dermatitis
Treatment phase: Dose change (increasing up to the 30 mg dose, or, decreasing back down to the 15 mg
dose) - whole body, or, face/hands
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 3 | DPMQ: $1,212.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||